Metavas MR

Metavas MR Uses, Dosage, Side Effects, Food Interaction and all others data.

Metavas MR is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity, which results in a reduction in fatty acid oxidation and a stimulation of glucose oxidation. High fatty acid oxidation rates are detrimental during ischemia due to an inhibition of glucose oxidation leading to uncoupling of glycolysis and an increase in proton production, which has the potential to accelerate sodium and calcium overload in the heart. This leads to an exacerbation of ischemic injury and decreased cardiac efficiency during reperfusion.

Metavas MR is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. Patients should be counselled regarding the risk of use with reduced renal or hepatic function, worsening of extrapyramidal symptoms or other movement disorders, and risk of falls.

Trade Name Metavas MR
Generic Trimetazidine
Trimetazidine Other Names Trimetazidina, Trimetazidine
Weight 35mg
Type Tablet (Modified Release)
Formula C14H22N2O3
Weight Average: 266.341
Monoisotopic: 266.163042576
Protein binding

Trimetazidine is 15% protein bound in plasma. Trimetazidine can bind to human serum albumin.

Groups Approved, Investigational
Therapeutic Class Other Anti-anginal & Anti-ischaemic drugs
Manufacturer NIPRO JMI Pharma Ltd
Available Country Bangladesh
Last Updated: September 19, 2023 at 7:00 am
Metavas MR
Metavas MR

Uses

Long-term treatment of Ischaemic heart disease (angina pectoris, sequelae of infarction).

Metavas MR is also used to associated treatment for these conditions: Angina Pectoris, Chronic Stable Angina Pectoris, Dizziness, Tinnitus, Decreased visual acuity caused by Vascular Disorders

How Metavas MR works

During myocardial ischemia, anaerobic metabolism takes over, increasing levels of lactic acid. The decreased intracellular pH and increased concentration of protons activates sodium-hydrogen and sodium-calcium antiport systems, raising intracellular calcium concentrations, finally leading to decreased contractility.

This injury to the myocardium raises concentrations of catecholamines, which activate hormone sensitive lipase, and increasing fatty acid concentrations in plasma. When the myocardium is repurfused, fatty acid oxidation becomes the dominant form of ATP production, maintaining an acidic pH, and further exacerbating the injury.

The mechanism of action of trimetazidine is not fully understood. Metavas MR may inhibit mitochondrial 3-ketoacyl coenzyme A thiolase, decreasing long chain fatty acid β-oxidation but not glycolysis in the myocardium. The decreased long chain fatty acid β-oxidation is compensated for by increased use of glucose, preventing a lowered myocardial pH, and further decreases in contractility. However, another study suggests that 3-ketoacyl coenzyme A thiolase may not be trimetazidine's target, and that this mechanism may be incorrect.

Dosage

Metavas MR dosage

One 20 mg tablet thrice daily after meals. No dosage adjustments are required in patients with impaired renal and hepatic function.

One 35 mg modified release tablet twice daily at mealtimes in the morning and evening.

Side Effects

Metavas MR is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.

Toxicity

Data regarding overdoses of trimetazidine are not readily available. Treat overdoses with symptomatic and supportive therapy.

The oral LD50 in rats is 1700 mg/kg, and in mice is 1550 mg/kg. The subcutaneous LD50 in rats is 1500 mg/kg, and in mice is 410 mg/kg.

Interaction

No drug interactions have so far been reported. In particular, no interactions of Metavas MR with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis have been reported.

Food Interaction

  • Take with food. Take during a meal.
  • Take with plain water. Take with a glass of water.

Volume of Distribution

The volume of distribution of trimetazidine is 4.8 L/kg.

Elimination Route

In elderly patients, a 35 mg oral modified release tablet reaches a mean Cmax of 115 µg/L, with a Tmax of 2.0-5.0 hours, and a mean AUC0-12 of 1104 h*µg/L. In young, healthy patients, the same dose reaches a mean Cmax of 91.2 µg/L, with a Tmax of 2.0-6.0 hours, and an AUC0-12h 720 h*µg/L.

Half Life

In young, healthy subjects, the half life of trimetazidine is 7.81 hours. In patients over 65, the half life increases to 11.7 hours.

Clearance

Metavas MR clearance is strongly correlated with creatinine clearance. In eldery patients with a creatinine clearance of 72 ± 8 mL/min, trimetazidine clearance was 15.69 L/h. In young, healthy patients with a creatinine clearance of 134 ± 18 mL/min, trimetazidine clearance was 25.2 L/h.

Elimination Route

Metavas MR is 79-84% eliminated in the urine, with 60% as the unchanged parent compound. In a study of 4 healthy subjects, individual metabolites made up 0.01-1.4% of the dose recovered in urine. In the urine, 2-desmethyltrimetazidine made up 0-1.4% of the recovered dose, 3- and 4-desmethyltrimetazidine made up 0.039-0.071% each, N-methyltrimetazidine made up 0.015-0.11%, trimetazidine ketopiperazine made up 0.011-0.4%, N-formyltrimetazidine made up 0.035-0.42%, N-acetyltrimetazidine made up 0.016-0.19%, desmethyl trimetazidine O-sulphate made up 0.01-0.65%, and an unknown metabolite made up0.026-0.67%.

Pregnancy & Breastfeeding use

Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.

Nursing Mothers: There is no information on the secretion of Metavas MR into breast milk. However, breast feeding should be discontinued if the use of Metavas MR is considered essential.

Contraindication

Hypersensitivity to Metavas MR Dihydrochloride.

Storage Condition

Store in a cool and dry place, protect from light and moisture. Keep out of the reach of children.

Innovators Monograph

You find simplified version here Metavas MR

Metavas MR contains Trimetazidine see full prescribing information from innovator Metavas MR Monograph, Metavas MR MSDS, Metavas MR FDA label

FAQ

What is Metavas MR used for?

Metavas MR used to prevent and treat the symptoms of angina (chest pain).

How safe is Metavas MR?

Metavas MR has been generally very well tolerated in clinical trials and usually only isolated cases of adverse events were observed during Metavas MR treatment.

What are the common side effects of Metavas MR?

The most common side effects are include nausea, vomiting, fatigue, dizziness, and myalgia. The drug can induce or increase parkinsonian symptoms: extrapyramidal rigidity, bradykinesia, and tremor.

Is Metavas MR safe during pregnancy?

The potential risk for humans is unknown.Metavas MR should not be taken during pregnancy unless clearly necessary.

Is Metavas MR safe during breastfeeding?

This medicinal product is generally not recommended during breastfeeding.Lactation It is unknown whether Metavas MR is excreted in human or animal breast milk.

Does Metavas MR effect my kidney?

Metavas MR is contraindicated in patients with severe renal impairment.

When should I take Metavas MR?

The recommended dose of Metavas MR is one tablet to be taken two times a day during meals in the morning and evening.For patients with moderate renal impairment and the elderly, the dose should be reduced.

Is Metavas MR good for the heart?

Metavas MR improves cardiac function by improving hemodynamics.

Can I take Metavas MR once a day?

Metavas MR is taken twice, or three times, each day. A new altered form of Metavas MR, which can be taken once a day, may improve patient-satisfaction.

Does Metavas MR lower heart rate?

The dose of Metavas MR does not affect hemodynamic stability, heart rate, blood pressure and speed-pressure multiplication, and it exerts no negative inotropic effect.

How long can I take Metavas MR?

Metavas MR usual treatment for up to 18 months was well tolerated and induced a functional improvement in patients with dilated cardiomyopathy.

Can I stop taking Metavas MR?

Metavas MR must be taken regularly for it to be effective. Continue taking this medicine even when you feel better. Do not stop taking it unless instructed by the doctor.

What happens if you stop taking Metavas MR?

Discontinuing Metavas MR treatment in people with Parkinson's disease may lessen their motor and non-motor symptoms and improve their quality of life, a study has found.

What is the benefit of taking Metavas MR?

the benefit of taking  Metavas MR helps to maintain the energy metabolism of heart muscle cells, protecting them from the effects of reduced oxygen supply.

What happen if I miss Metavas MR?

If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Then take your next dose at the usual time. Do not take two doses to make up for the missed dose.

Does Metavas MR lower heart rate?

The dose of Metavas MR does not affect hemodynamic stability, heart rate, blood pressure and speed-pressure multiplication, and it exerts no negative inotropic effect.

Can Metavas MR cause drowsiness?

Metavas MR does not have haemodynamic effects in clinical studies, however cases of dizziness and drowsiness have been observed in post-marketing experienc.

*** Taking medicines without doctor's advice can cause long-term problems.
Share